|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Trevena, Inc. Angiotensin Receptor Biased Ligand Promotes Cell Survival During Acute Cardiac Injury
9/4/2012 3:39:55 PM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced that results from a study into the cardioprotective actions of its Angiotensin II Type 1 Receptor (AT1R) biased ligands has been published. The publication describes the results of experiments conducted at Duke University in the laboratory of Dr. Howard Rockman, in collaboration with Trevena, showing that ß-arrestin biased AT1R ligands can protect cardiac tissue from injury. The molecule tested, TRV120023, is closely related to TRV027, Trevena’s experimental acute heart failure molecule currently in mid-stage clinical trials.
|
|
|
|
|
|
|
|
|
|
|